Clinical trial
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early…
NCT00050531 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00050531 |
|---|---|
| Title | High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) |
| Official title | Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Drug |
| Interventions | Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF) |
| Enrollment | 94 |
| Start date | Apr 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2015 |
| First posted | Feb 7, 2003 |
| Last update posted | May 11, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: